Welcome : Guest

BeiGene Ltd. (Cayman Islands) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about BeiGene Ltd., which is principally a Biopharmaceutical Company. Illustrated with 34 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-65953
Price: $1700
Company Type: Public
Pages: 37
Date: January 2017
Market Data Tables: 34

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Monoclonal Antibodies......4
Table 1: Monoclonal Antibodies Market by Drugs Worldwide (2015) - Percentage Share Breakdown by Value for Avastin, Crestor, Enbrel, Humira, Lantus, Remicade and Others......4
Table 2: Antiviral Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Antiviral Drugs, Monoclonal Antibodies, Vaccines and Others......5
Table 3: Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Biologics, Monoclonal Antibodies and Other Classes......6
Table 4: Therapeutic Development Market by Product Worldwide (2015) - Percentage Share Breakdown by Volume for Cell Therapy, Monoclonal Antibodies, Vaccines and Others......7
Table 5: Biotechnology Drugs by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Cell Therapy, Gene Therapy, Monoclonal Antibodies (MAB), Recombinant Hormones and Proteins, Vaccines, and Others......8
Table 6: Proteins Market by Segment in China (2015) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Granulocyte Colony Stimulating Factor (GCSF), Insulin, Interferon, Interleukin, Monoclonal Antibody (MAb), Nerve Growth Factor (NGF), and Somatropin......9
Table 7: Therapeutic Biologics Market by Type in China (2015) - Percentage Share Breakdown by Value for Erythropoietin (EPO), Granulocyte Colony-Stimulating Factor (GCSF), Insulin, Interferon, Interleukin, Monoclonal Antibodies (MAb), Nerve GF, Somatropin, and Others......10
Cancer Drugs......11
Table 8: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......11
Table 9: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......12
Cancer Market......13
Table 10: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......13
Table 11: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......14
Table 12: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......15
Table 13: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......16
Table 14: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......17
Table 15: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......18
Table 16: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......19
Table 17: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......20
Cancer Patients......21
Table 18: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......21
Table 19: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......22
Table 20: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......23
Table 21: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......24
Chronic Myelogenous Leukemia (CML)......25
Table 22: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......25
Multiple Myeloma......26
Table 23: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......26
Table 24: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......27
Hematological Cancer......28
Table 25: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......28
Monoclonal Antibodies......29
Table 26: Market Shares of Leading Monoclonal Antibody Production Companies in the US (2015) - Percentage Share Breakdown by Value for Abbvie Inc., AMGen, Johnson & Johnson, F. Hoffmann-La Roche AG and Others......29
Cancer Drugs......30
Table 27: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......30
Table 28: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......31
Table 29: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......32
Table 30: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......33
Table 31: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......34
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......35
Table 32: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......35
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......36
Table 33: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......36
Table 34: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......37